This multicenter report, titled “Exchange transfusion and systemic corticosteroid therapy for transient abnormal myelopoiesis in patients with Down syndrome,” summarizes work from the JCCG TAM-10 trial and was published in Eur J Pediatr on 26 August 2026 (185[9]:692). The PubMed record (PMID 42642489; DOI 10.1007/s00431-026-07351-1) identifies the topic and the contributing authors but the excerpt provided does not include the article abstract or full text.
Transient abnormal myelopoiesis (TAM) is a neonatal myeloproliferative condition uniquely associated with infants with Down syndrome. The JCCG TAM-10 trial, as indicated by the article title, evaluated two therapeutic strategies—exchange transfusion and systemic corticosteroid therapy—targeting TAM in this specific patient population.
The work is described as a multicenter study and is authored by a collaborative group led by Kyogo Suzuki and Daisuke Hasegawa, among others. The full author list appears in the PubMed entry and includes pediatricians and pediatric hematology/oncology specialists from multiple Japanese institutions. The trial is referred to as the JCCG TAM-10 trial in the article title; however, the PubMed snippet supplied here does not contain a structured abstract or trial registry information.
Publication identifiers available from the source are:
These identifiers permit retrieval of the full manuscript for detailed methods and results.
The author group comprises clinicians from a range of Japanese pediatric centers. Representative affiliations listed in the PubMed entry include:
The multicenter composition indicates collaboration across tertiary pediatric and pediatric hematology-oncology services.
The article title indicates that exchange transfusion was evaluated as one of the interventions for neonates with TAM associated with Down syndrome under the JCCG TAM-10 protocol. Exchange transfusion is a procedural therapy used in neonates for removal of circulating pathological blood elements or toxic substances and replacement with donor blood; its use in TAM would be aimed at rapidly reducing the circulating abnormal myeloid cell burden and addressing complications such as hyperviscosity or organ dysfunction.
The PubMed snippet does not provide procedural details such as indications for exchange transfusion in the trial, timing, exchange volume, replacement product, peri-procedural monitoring, or observed efficacy and safety outcomes. Those specifics are not reported in the provided source text and must be obtained from the full published report.
The second intervention named in the title is systemic corticosteroid therapy. Corticosteroids may be used in neonatal hematologic disorders to modulate inflammation or cell proliferation. The exact corticosteroid agent(s), dosing schedules, duration of therapy, indications for initiation, and reported effects in the TAM-10 cohort are not documented in the PubMed excerpt provided here.
Without the full article text, no validated statements about corticosteroid efficacy, safety, or recommended regimens can be extracted from the source material given.
The PubMed record identifies the study as multicenter and lists authors and affiliations, but it does not include key methodological elements in the text provided to this rewrite task. Missing items in the available source text include:
Because these critical elements are not present in the supplied excerpt, they cannot be reproduced or summarized here without consulting the full journal article.
This rewritten summary is strictly limited to the bibliographic and title-level information available in the PubMed entry. The full abstract, methods, results, and discussion were not included in the source text provided for this task. As a result, no outcome data, numerical results, or authors’ conclusions can be restated; doing so would require access to the full published manuscript or journal abstract.
From the PubMed metadata we can confirm that the JCCG TAM-10 trial addressed the roles of exchange transfusion and systemic corticosteroid therapy in neonates with transient abnormal myelopoiesis and Down syndrome, and that the full report is published in a peer-reviewed pediatric journal with DOI and PMID for retrieval.
Clinicians and researchers seeking actionable clinical guidance or outcome data should access the full article via the DOI or PubMed entry to review the study’s design, patient population, detailed interventions, measured outcomes, and authors’ conclusions. Until those data are examined, no evidence-based practice changes or recommendations can be inferred from the title and citation alone.
For retrieval: use DOI 10.1007/s00431-026-07351-1 or PubMed PMID 42642489 to obtain the complete manuscript and verify trial findings, safety data, and any protocol recommendations from the JCCG TAM-10 investigators.